Abstract
Kinins (bradykinin, kallidin and their active metabolites) are peptide autacoids with established functions in cardiovascular homeostasis, contraction and relaxation of smooth muscles, inflammation and nociception. They are believed to play a role in disease states like asthma, allergies, rheumatoid arthritis, cancer, diabetes, endotoxic and pancreatic shock, and to contribute to the therapeutic effects of ACE inhibitors in cardiovascular diseases. Although kinins are also neuromediators in the central nervous system, their involvement in neurological diseases has not been intensively investigated thus far. This review analyzes the potential of central kinin receptors as therapeutic targets for neurological disorders. Initial data highlight potential roles for B1 receptor antagonists as antiepileptic agents, and for B2 receptor antagonists (and/or B1 agonists) in the treatment of stroke. Functional B1 receptors located on T-lymphocytes and on the blood brain-barrier are also putative targets for the management of multiple sclerosis. However, successful elucidation of the therapeutic value of these new pharmacological approaches will require refinement of our knowledge on the physiology and cellular localization of central kinin receptors.
Keywords: bradykinin, b1 receptors, b2 receptors, brain, neurological diseases, epilepsy, pain, diabetes, hypertension
Current Pharmaceutical Design
Title: Targeting Kinin Receptors for the Treatment of Neurological Diseases
Volume: 11 Issue: 10
Author(s): D. Rodi, R. Couture, B. Ongali and M. Simonato
Affiliation:
Keywords: bradykinin, b1 receptors, b2 receptors, brain, neurological diseases, epilepsy, pain, diabetes, hypertension
Abstract: Kinins (bradykinin, kallidin and their active metabolites) are peptide autacoids with established functions in cardiovascular homeostasis, contraction and relaxation of smooth muscles, inflammation and nociception. They are believed to play a role in disease states like asthma, allergies, rheumatoid arthritis, cancer, diabetes, endotoxic and pancreatic shock, and to contribute to the therapeutic effects of ACE inhibitors in cardiovascular diseases. Although kinins are also neuromediators in the central nervous system, their involvement in neurological diseases has not been intensively investigated thus far. This review analyzes the potential of central kinin receptors as therapeutic targets for neurological disorders. Initial data highlight potential roles for B1 receptor antagonists as antiepileptic agents, and for B2 receptor antagonists (and/or B1 agonists) in the treatment of stroke. Functional B1 receptors located on T-lymphocytes and on the blood brain-barrier are also putative targets for the management of multiple sclerosis. However, successful elucidation of the therapeutic value of these new pharmacological approaches will require refinement of our knowledge on the physiology and cellular localization of central kinin receptors.
Export Options
About this article
Cite this article as:
Rodi D., Couture R., Ongali B. and Simonato M., Targeting Kinin Receptors for the Treatment of Neurological Diseases, Current Pharmaceutical Design 2005; 11 (10) . https://dx.doi.org/10.2174/1381612053507422
DOI https://dx.doi.org/10.2174/1381612053507422 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery The Role of Bacterial DNA in Inflammatory and Allergic Disease
Recent Patents on Inflammation & Allergy Drug Discovery Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Current Pharmaceutical Design 5-Lipoxygenase: A Promising Drug Target Against Inflammatory Diseases-Biochemical and Pharmacological Regulation
Current Drug Targets Recent Advances in Inorganic Nanoparticle-Based Drug Delivery Systems
Mini-Reviews in Medicinal Chemistry Application of Immunological Techniques (from Vaccination to Final Measurements) in Determination of Pharmaceutical Residues in Environmental Samples
Current Analytical Chemistry Synthetic Peptides in the Diagnosis of Systemic Autoimmune Diseases
Current Protein & Peptide Science From the Stretcher to the Pharmacys Shelf: Drug Leads from Medically Important Brazilian Venomous Arachnid Species
Inflammation & Allergy - Drug Targets (Discontinued) Role of Topological, Electronic, Geometrical, Constitutional and Quantum Chemical Based Descriptors in QSAR: mPGES-1 as a Case Study
Current Topics in Medicinal Chemistry Applications of Barton-McCombie Reaction in Total Syntheses
Current Organic Synthesis Vitamin D Receptor Agonists: Opportunities and Challenges in Drug Discovery
Current Topics in Medicinal Chemistry Cholinergic Targets in Lung Cancer
Current Pharmaceutical Design Recent Advances in Anti-Survivin Treatments for Cancer
Current Medicinal Chemistry Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Measures of Disease Activity in Rheumatoid Arthritis: A Clinicians Guide
Current Rheumatology Reviews Structure-Based Rationale for Interleukin 5 Receptor Antagonism
Current Pharmaceutical Design Serine Proteases in Bone Disease
Current Rheumatology Reviews